Geoffrey Swire

Geoffrey Swire joined the Hopewell team in November 2022 as a strategy consultant and advisor. He has over 20 years of leadership experience in business, product, and commercial development for life sciences companies.   

​

Mr. Swire’s most recent roles have focused on helping development stage biotechnology companies raise capital, advance their programs, and scale their capabilities toward commercialization. As Acting COO and SVP of Corporate Development at Allena Pharmaceuticals, Mr. Swire’s responsibilities spanned external partnering efforts and internal R&D program operations. Prior to Allena, Mr. Swire helped Radius Health complete its highly successful IPO and gain FDA approval for its osteoporosis product, Tymlos, serving as head of business development and alliance management, and earlier as program leader for the global Phase 3 Tymlos program. Before Radius, Mr. Swire spent seven years at Genzyme in various leadership positions in the Transplant and Oncology business units. While at Genzyme, he played a central role in the acquisition, development, regulatory approvals, and global commercial launch of Mozobil for patients undergoing stem cell transplants. Mr. Swire started his career in strategy and product development consulting at Integral, Inc., and Accenture’s Health & Life Sciences practice. 

​​

Mr. Swire holds a B.A. in French and History from Dartmouth College

and an M.P.P. from Harvard University.